Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Pharvaris today and set a price target of $60.00.

Patrick Trucchio has given his Buy rating due to a combination of factors, primarily the advancement of Pharvaris’s late‑stage deucrictibant franchise across multiple hereditary and acquired angioedema settings. He highlights the completion of enrollment in the pivotal CHAPTER‑3 Phase 3 prophylaxis trial, the maintained timeline for a 3Q26 topline readout, and the planned 1H26 NDA submission for the on‑demand capsule formulation supported by positive RAPIDe‑2 and RAPIDe‑3 data.

He also points to progress in the CREAATE Phase 3 study in acquired C1‑inhibitor deficiency angioedema, which he views as a meaningful expansion opportunity into a largely untreated market. Trucchio underscores the company’s strong balance sheet, with year‑end cash of about €292 million expected to fund operations through the CHAPTER‑3 data readout into 1H27, and models substantial peak revenue potential for deucrictibant in prophylaxis, supporting his reiterated Buy rating and $60 price target.

In another report released today, RBC Capital also maintained a Buy rating on the stock with a $51.00 price target.